Pinilla-Ibarz Javier, Shah Bijal, Dubovsky Jason A
Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.
Cancer Control. 2009 Apr;16(2):141-52. doi: 10.1177/107327480901600206.
Chronic myelogenous leukemia (CML) has long been recognized as an entity responsive to immunotherapeutic interventions. Despite the success of the tyrosine kinase inhibitors (TKIs) in this disease, CML remains incurable. Only allogeneic bone marrow transplantation can provide long-term eradication of CML.
This review summarizes the recent advances in the field of immunology in CML, specifically in tumor antigen discovery, that have been incorporated into the design of new clinical trials.
Multiple vaccine approaches are currently under clinical investigation. Recent laboratory and clinical data also point to a unique interaction of TKIs with the immune system.
A better understanding of these interactions combined with advances in the field of immunotherapy will likely lead to incorporation of TKIs in future therapeutic interventions to develop a cure for this disease.
慢性粒细胞白血病（CML）长期以来一直被认为是一种对免疫治疗有反应的疾病。尽管酪氨酸激酶抑制剂（TKIs）在这种疾病中取得了成功，但CML仍然无法治愈。只有异基因骨髓移植才能长期根除CML。
本综述总结了CML免疫学领域的最新进展，特别是在肿瘤抗原发现方面，这些进展已被纳入新临床试验的设计中。
目前多种疫苗方法正在进行临床研究。最近的实验室和临床数据也表明TKIs与免疫系统存在独特的相互作用。
更好地理解这些相互作用以及免疫治疗领域的进展可能会导致在未来的治疗干预中纳入TKIs，以开发治愈这种疾病的方法。
